Select a Country Investors News Contact About Alexion Patient Focus Products Research & Development Responsibility Careers European Commission Approves Soliris® (eculizumab) for Treatment of Patients with Refractory gMG. Read the press release for more information. Seeing the Unseen for 25 Years For 25 years, Alexion has seen opportunities where others have not. We have had the courage to explore what others believe is impossible. And we have forged a pathway from innovative science to breakthrough therapies for patients suffering from rare diseases that had previously been overlooked. Learn More We see an opportunity to change lives. We have the passion to engineer our own course because the scientific challenges we choose to tackle require it. We are driven by our mission to bring hope to patients and families affected by rare diseases by delivering innovative, life-changing therapies. LATEST NEWS view all news FEATURED STORIES view all stories U.S. Green Building Council Awards Alexion Headquarters Highest LEED® Green Building Certification Alexion’s 2016 Annual Report and Commemorative Anniversary Booklet Now Available Alexion Celebrates 25th Anniversary on Rare Disease Day 2017 Alexion Ranked No. 8 in Science Top Employer Survey About Alexion Patient Focus Products Research and Development Responsibility Careers Investors News Contact Site Map Legal Statement Privacy Policy Terms of Use This website is intended only for residents of the United States. © 2017 Alexion